In ALK+ mNSCLC, Choose ALUNBRIG® (brigatinib)
First-Line

""
Category 1, Preferred NCCN Recommendation.

National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1 preferred first-line treatment option for ALK+ metastatic NSCLC1,c,d,e

CNS Efficacy

""

First-line results in ALK+ mNSCLC patients with brain metastases at baseline

Long-Term Tolerability

""

A well-established safety profile with long-term tolerability

Once-Daily Dosing

""

Helpful information on the one tablet, once-daily recommended dosage, and modifications for adverse reactions

Exploring key efficacy, safety, and patient case data

Dr. Alex Spira, Director of the Virginia Cancer Specialists Research Institute, discusses ALUNBRIG for the treatment of adult patients with ALK+ mNSCLC.

Connect with our team

Learn more about first-line ALUNBRIG for patients with ALK+ mNSCLC from an ALUNBRIG representative.

aBased on a post-hoc subgroup analysis.
bLong-term tolerability is based on the median follow-up in the ALUNBRIG arm of ALTA 1L: 40.4 months.
cWhen an ALK rearrangement is discovered prior to first-line systemic therapy.
dThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
eSee the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.

ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; FDA, Food and Drug Administration; mets, metastases; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer.